Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT03543969Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of encorafenib and binimetinib in melanoma (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: 8 Week Completion Rate. Started Jun 2018; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03543969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543969.